Suven Life Sciences Limited has informed the Exchange regarding a press release dated May 12, 2026, titled "Suven Life Sciences Reaches 76% Enrollment milestone in Global Phase 3 Masupirdine (SUVN-502) Trial for Agitation in Alzheimer s Dementia".
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Suven Life Sciences has achieved a 76% enrollment milestone in its global Phase 3 clinical trial for Masupirdine (SUVN-502), an investigational drug for treating agitation in patients with Alzheimer's dementia. The trial involves 375 patients across approximately 80 sites in North America and Europe. The company expects to complete patient enrollment by September 2026 and last patient last visit by January 2027, with data readout anticipated by April 2027. Masupirdine is a selective 5-HT6 receptor antagonist offering a non-dopaminergic, non-sedative approach to managing Alzheimer's agitation.
This is a positive clinical development showing the trial is progressing well. However, shareholders should note the drug is still years away from potential approval and commercialization, with no immediate revenue impact. The successful trial completion could significantly enhance the company's value proposition in the CNS disorders space.